James Dale BS, PhD

James has over 18 years’ experience in synthetic and medicinal chemistry, working in the Big Phrama and the Biotech sectors. During his time at Novartis, James worked on programmes focused on developing small molecule therapeutics in the areas of respiratory and gastrointestinal diseases and was lead chemist on number of Hit-2-Lead and Lead-Op campaigns. While at Proximagen, he led a team of scientists working on a CNS target with a novel mode of action. James is now heading the chemistry efforts at Nanna Therapeutics, utilising the proprietary integrated T.I.M.E platform and in particular Encoded Library Technology in Nanospheres in order to identity novel therapeutics across a breadth of therapeutic indications.